Trial | NCT03164291  Report issue

Title

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    rifabutin ...

  • Study Participants

    170
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.

Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin.
Study Started
Jun 30
1984
Primary Completion
Sep 30
2006
Study Completion
May 18
2017
Last Update
May 23
2017

Drug Rifabutin

Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status

  • Other names: mycobutin

Rifabutin Experimental

Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)

Criteria 

Inclusion Criteria:

Adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria

Exclusion Criteria:

Children less than 18 years of age
Pregnancy
Low platelet count, except with very serious disease
No Results Posted